NIKKEI 225
38,610.16 -310.10 (-0.80%) HANG SENG
19,376.53 +302.82 (+1.59%) CRUDE OIL
79.34 +0.11 (+0.14%) GOLD FUTURES
2,382.90 -2.60 (-0.11%) DOW
39,869.38 -38.62 (-0.10%) Bitcoin GBP
51,605.75 -711.45 (-1.36%)
Royalty Pharma plc (RPRX)
After hours:
| Previous close | 28.00 |
| Open | 28.01 |
| Bid | 27.82 x 300 |
| Ask | 27.88 x 500 |
| Day's range | 27.83 - 28.20 |
| 52-week range | 25.92 - 34.65 |
| Volume | |
| Avg. volume | 2,753,968 |
| Market cap | 16.657B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 15.66 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.84 (2.98%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcast
- GlobeNewswire
Royalty Pharma Reports First Quarter 2024 Results
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We con
- GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIR
